1. Volume 14, Issue 12, Pages 1208-1215 (November 2013)
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial 
Prof Bernard Nordlinger, MD, Prof Halfdan Sorbye, MD, Prof Bengt Glimelius, MD, Prof Graeme J Poston, MD, Prof Peter M Schlag, MD, Prof Philippe Rougier, MD, Prof Wolf O Bechstein, MD, Prof John N Primrose, MD, Euan T Walpole, MBBS, Meg Finch-Jones, MD, Prof Daniel Jaeck, MD, Darius Mirza, FRCS, Rowan W Parks, MD, Murielle Mauer, PhD, Erik Tanis, MD, Prof Eric Van Cutsem, MD, Prof Werner Scheithauer, MD, Thomas Gruenberger, MD 
The Lancet Oncology 
Volume 14, Issue 12, Pages (November 2013)
DOI: /S (13)
Copyright © 2013 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
*37 patients who had a tumour resection were not given postoperative chemotherapy; 68 of all patients assigned to perioperative chemotherapy were not given postoperative chemotherapy.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

3. Figure 2 Overall survival
Kaplan-Meier curves of overall survival in all randomly assigned patients (A) and all eligible patients (B) per treatment group.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

4. Figure 3 Progression-free survival (long-term update)
Kaplan-Meier curves of progression-free survival in all randomly assigned patients (A) and all eligible patients (B) per treatment group.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions